Drug Trial Radar · NCT07402369
Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia
Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 19, 2026
Primary completion
Jan 3, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective This study evaluates whether CMS-D002 capsules are effective in treating menorrhagia in participants with uterine fibroids associated with menorrhagia. The primary outcome is the percentage of participants who achieve menstrual blood loss \<80 mL and a reduction of ≥50% from baseline. Study Design This is a placebo-controlled trial. Participants will be randomized to receive either CMS-D002 capsules or a matching placebo for 12 weeks. Participant Responsibilities Take one CMS-D002 capsule or placebo daily for 12 weeks. Complete an electronic patient diary daily throughout the study to record menstrual bleeding and other symptoms.
Conditions
- Uterine Fibroids With Menorrhagia
Interventions
CMS-D002 Capsules 10 mgDrug
CMS-D002 Capsules 10 mg, QD
CMS-D002 Capsules 25 mgDrug
CMS-D002 Capsules 25 mg, QD
CMS-D002 Capsules 50 mgDrug
CMS-D002 Capsules 50 mg, QD
PlaceboDrug
Placebo, QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with menstrual bleeding < 80 mL and a reduction of ≥50% from baselineTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.